Recently, increased RBM3 nuclear expression was also linked to cisplatin sensitivity and to an improvement in the prognosis in epithelial ovarian cancers [23, 24], as well as to a prolonged time to disease progression in prostate cancer [25]. Here, RBM3 is linked to Familial prostate cancer.